°øÁö»çÇ×

2018³â ´ëÇѾÏÇÐȸ Çмú»ó ¼ö»óÀÚ
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
ÀÛ¼ºÀÏ
2018-07-10
Á¶È¸
2478
2018³â ´ëÇѾÏÇÐȸ Çмú»ó ¼ö»óÀÚ ¸í´Ü
1. Á¦ 21ȸ Çѱ¹¾Ï¿¬±¸Àç´Ü Çмú»ó (CRT¿¡ °ÔÀçµÈ ±âÃÊ³í¹®, »ó±Ý 500¸¸¿ø)
No. ¼ö»óÀÚ Á¦¸ñ ÆäÀÌÁö¹øÈ£
1 ¼Û¿ë»ó(¼­¿ïÀÇ´ë »êºÎÀΰú) Adipose Stromal Cells from Visceral and Subcutaneous Fat Facilitate Migration of Ovarian Cancer Cells via IL-6/JAK2/STAT3 Pathway (2)338-349
2. Á¦ 10ȸ ´ëÇѾÏÇÐȸ ±âÃÊ¿ì¼ö³í¹®»ó (CRT¿¡ °ÔÀçµÈ ±âÃÊ³í¹®, »ó±Ý °¢ 250¸¸¿ø)
No. ¼ö»óÀÚ Á¦ ¸ñ ÆäÀÌÁö¹øÈ£
1 ÀÌÈñÁø(¼­¿ï¾Æ»êº´¿ø º´¸®°ú) Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer (2)399-407
2 ÃÖ°æö(ÃæºÏ´ë ¼öÀÇÇаú) Anti-proliferative Effect of Engineered Neural Stem Cells Expressing Cytosine Deaminase and Interferon-β against Lymph Node–Derived Metastatic Colorectal Adenocarcinoma in Cellular and Xenograft Mouse Models (1)79-91
3. Á¦ 8ȸ ¸ÓÅ© ¾ÏÇмú»ó (CRT¿¡ °ÔÀçµÈ ÀÓ»ó³í¹® Áß ´ëÀå¾Ï ¶Ç´Â µÎ°æºÎ ³í¹®, »ó±Ý °¢ 200¸¸¿ø)
No. ¼ö»óÀÚ Á¦ ¸ñ ÆäÀÌÁö¹øÈ£
1 Á¶»óÈñ (Àü³²ÀÇ´ë ³»°ú) FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition (3)766-777
2 ±èÅ¿ø(¼­¿ï¾Æ»êº´¿ø ³»°ú) Use of a High-Throughput Genotyping Platform (OncoMap) for RASMutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer (1)37-43
3 ¼­¿µÁø(°¡Å縯ÀÇ´ë ¿Ü°ú) The Prognostic Values of Preoperative Tumor Volume and Tumor Diameter in T1N0 Papillary Thyroid Cancer (4)890-897
4. Á¦ 10ȸ ·Î½´ ¾ÏÇмú»ó (CRT¿¡ °ÔÀçµÈ ÀÓ»ó & Translational ³í¹® 10Æí, »ó±Ý °¢ 200¸¸¿ø)
No ¼ö»óÀÚ Á¦ ¸ñ ÆäÀÌÁö¹øÈ£
1 ¹é¹«ÁØ(¼øõÇâÀÇ´ë ¿Ü°ú) Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma (1)246-254
2 ³ëÁ¤½Ç(±¹¸³¾Ï¼¾ÅÍ ³»°ú) An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer (3)569-577
3 ±èµ¿±Ô, ¹Úö±â (¼­¿ïÀÇ´ë ½Å°æ¿Ü°ú) Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma (2)387-398
4 ±è¿µÅÂ(¿¬¼¼ÀÇ´ë »êºÎÀΰú) Long Non-coding RNA HOXA11 Antisense Promotes Cell Proliferation and Invasion and Predicts Patient Prognosis in Serous Ovarian Cancer (3)656-668
5 ½Å°æȯ(¼­¿ïÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) Incorporating Risk Factors to Identify the Indication of Post-Mastectomy Radiotherapy in N1 Breast Cancer Treated with Optimal Systemic Therapy: A Multicenter Analysis in Korea (KROG 14-23) (3)739-747
6 ¿ø¿µÁÖ(±¹¸³¾Ï¼¾ÅÍ ¾Ïµî·Ï»ç¾÷ºÎ) Lung Cancer Epidemiology in Korea (3)616-626
7 ÀÌâ°É(¿¬¼¼ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú) Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy (3)669-677
8 ½Å»óÁØ(¿¬¼¼ÀÇ´ë ³»°ú) Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort (1)44-53
9 ³²ÀºÁö(¿¬¼¼ÀÇ´ë »êºÎÀΰú) Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients (2)408-415
10 °ø¼±¿µ(±¹¸³¾Ï¼¾ÅÍ Áø´Ü°Ë»çÀÇÇаú) Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes among Korean Breast Cancer Patients (3)627-634
ÀÌÀº¼÷(±¹¸³¾Ï¼¾ÅÍ ¿Ü°ú)
5. Á¦ 7ȸ ±¤µ¿¾ÏÇмú»ó
  1) ÃÖ°í IF SCI ÇмúÁö¿¡ CRT ³í¹®À» ÀοëÇÏ¿© ³í¹®À» ¹ßÇ¥ÇÑ ±âÃÊ ¹× ÀÓ»ó ºÐ¾ßÀÇ Ã¥ÀÓÀúÀÚ °¢ 1¸í
No ÀúÀÚ ¹× ¼Ò¼Ó ³í¹®Á¦¸ñ °ÔÀçÇмúÁö
1 ¹ÚÀºÃ¶(¿¬¼¼ÀÇ´ë ¿¹¹æÀÇÇб³½Ç) Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality Gastroenterology. 2017 May;152(6):1319-1328.
Ãֱͼ±(±¹¸³¾Ï¼¾ÅÍ ¾Ï°ËÁø»ç¾÷°ú)
2 ±èÁ¾ÀÏ(¼­¿ïÀÇ´ë »ýÈ­Çб³½Ç) Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer Nat Commun. 2017 Jul 13;8:15966.
¹Ú¿µÁÖ(¼­¿ïÀÇ´ë ³»°ú)
ÀÌÀº°æ(±¹¸³¾Ï¼¾ÅÍ ³»°ú)
  2) ´Ù¼öÀÇ SCI µîÀç ÇмúÁö¿¡ CRT ³í¹®À» ÀοëÇÏ¿© ³í¹®À» ¹ßÇ¥ÇÑ Ã¥ÀÓ ÀúÀÚ 1¸í
No ¼ö»óÀÚ ³í¹®Á¦¸ñ °ÔÀçÇмúÁö
1 ±èÁ¤ÇÑ(ÇѸ²ÀÇ´ë ³»°ú) The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta- analysis of randomized trials Oncotarget. 2017 Aug 17;8(42):73009-73016.